Optimum novel pharmaceutical launch price
Case Studies

Optimum novel pharmaceutical launch price


Securing the optimum launch price for a novel pharmaceutical product across 31 EU countries

Development and implementation of the optimum price submission strategy for a product in the EU.

The challenge

Our client sought our expertise to support them in the development and submission of the optimum pricing dossiers for their novel product across 31 European markets covered by EMA’s centralized procedure.

The solution

Remap Consulting undertook a four-step approach to ensure that the prices across the 31 EU markets could be secured in accordance with the client’s overall EU objectives and launch timelines.

Value to the client

Partnering with Remap Consulting enabled our client to:

  • Develop a robust pricing strategy and launch roadmap for the EU
  • Identify the evidence gaps and put workable solutions in place to address them
  • Optimize price submission dossiers, through access to country-specific expertise, to ensure submissions are adapted to country requirements
  • Secure EU launch prices, aligned with the client’s launch expectations thereby facilitating patient access to the product
  • Achieve patient access at a price that represents value to both the country stakeholders and company within their stated timelines


You guys are awesome. Your expertise and responsiveness are second to none. Without your support we could never have achieved an EU launch.

Senior Director, Marketing

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.